Dr. Hamed I. Ali is an Assistant Professor of Oncology related-Drug design and Medicinal Chemistry Research in the Department of Pharmaceutical Science at Rangel College of Pharmacy (RCOP), Texas A&M Health Science Center, Texas. He did his postdoctoral training in at Texas A&M University. He obtained his PhD in Medicinal Chemistry and Computer Aided-Drug Design at Okayama University, Japan, in 2007. Since that, He has acquired an ample experience in the drug discovery research. He has published more than 50 peer-reviewed articles and he has served as ad hoc reviewer for a couple of journals in both fields. Currently, he has devoted his research career to design, synthesize, and biological screening of antitumor agents against a wide panel of tumor cell lines. Dr. Ali has an experience in the field of homology modeling and virtual high throughput screening (VHTS) which is the main integral part for drug discovery in the pharmaceutical industry. He also has an extensive experience in computational aided drug design and chemical synthesis for lead optimization to get the most potentially active and selective kinase inhibitors against breast cancer and leukemia. Dr. Hamed Ali is poised to build upon his findings to innovatively generate a new selective protein tyrosine kinase inhibitors (PTKIs) as antitumor agents that inhibit multiple features of cancer cells, including proliferation, survival, invasion, and angiogenesis. Moreover, he has merged this research with his dexterity in Virtual Screening to get new hits as CB1 selective (AMs) for the treatment of neurodegenerative diseases. At RCOP, Dr. Ali received multiple research grant funded by KACST, KSA. In addition, he has another 5 grants worth of $1.7 Million (as a PI, CO-I, and Consultant). He has completed other three research grants value $0.8 Million (as a group leader in drug design team). Dr. Ali has mentored many graduate students to design and synthesis different heterocyclic compounds of potential antitumor activities; many of them are currently pursuing their research in prestigious universities in the United States. The success with which his laboratory has glided between computational design and chemical synthesis of potential antitumor agents has prompted Dr. Ali to contribute to significant discoveries in this field.
Dr. Hamed Ali’s current and future ongoing research focus on targeting the aggressive HER2-resistant breast cancer by selective allosteric and flexible orthosteric kinase inhibitors. His main aim is to attain selective antitumor agents against specific PTks and to overcome the cancer cell drug resistance. Additionally, Dr. Ali’s current research was extended for the discovery of potent and selective antiangiogenic agents. This research involves the synthesis and biological evaluation of novel furochromone and benzofuran derivatives targeting VEGFR-2 TKs. Many of the designed analogues exhibited IC50 < 1.0 nM in comparison to Sorafenib (IC50: 2.0 nM). New 2-furyl-benzimidazoles analogs were also designed and synthesized as antiangiogenic agents which revealed potent VEGF inhibition in MCF-7 cancer cell line more potent than Tamoxifen.